Carlsmed (Nasdaq:CARL) today announced new technology add-on payment (NTAP) reimbursement for its spine implant technology.
CMS granted the reimbursement for cervical fusion procedures using the company’s Aprevo personalized interbody implants. Approval comes as part of the centers’ Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026.
NTAP provides additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. Starting Oct. 1, cervical fusion procedures utilizing Aprevo devices are eligible for additional payment from CMS and private payors. This provides up to an additional $21,125 in reimbursement for qualifying procedures.
Carlsbad, California–based Carlsmed designed the Aprevo devices to match the unique anatomical and alignment needs of each patient. The company’s proprietary AI-powered surgical planning platform and digital production system power the devices.
The company developed its AI-enabled personalized spine surgery. It already holds FDA breakthrough device designation for the Aprevo lumbar and cervical patient-specific interbody fusion devices. The implantable devices and software platforms hold FDA clearance for lumbar spine fusion. That includes anterior, lateral and transforaminal approaches.
Carlsmed announced the completion of the first successful cervical procedure using its Aprevo devices earlier this week. The company anticipates a U.S. launch next year. These positive developments come on the heels of Carlsmed going public through an IPO last week.
Building upon the CMS reimbursement granted to our lumbar fusion devices last year, we are pleased that this decision enables us to continue our mission to improve outcomes and decrease the cost of healthcare for spine surgery patients,” said Mike Cordonnier, chair and CEO of Carlsmed.
